aTyr Pharma, Inc. (ATYR)

NASDAQ: ATYR · Real-Time Price · USD
0.9656
-0.0072 (-0.74%)
At close: Oct 24, 2025, 4:00 PM EDT
0.9561
-0.0095 (-0.98%)
After-hours: Oct 24, 2025, 7:02 PM EDT
-0.74%
Market Cap94.62M
Revenue (ttm)n/a
Net Income (ttm)-66.64M
Shares Out 97.99M
EPS (ttm)-0.80
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,784,490
Open0.9879
Previous Close0.9728
Day's Range0.9441 - 0.9900
52-Week Range0.6816 - 7.2900
Beta0.79
AnalystsBuy
Price Target8.88 (+819.64%)
Earnings DateNov 11, 2025

About ATYR

aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; and in Phase 1b/2a clinical trial to treat other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease rela... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 7, 2015
Employees 65
Stock Exchange NASDAQ
Ticker Symbol ATYR
Full Company Profile

Financial Performance

In 2024, aTyr Pharma's revenue was $235,000, a decrease of -33.43% compared to the previous year's $353,000. Losses were -$64.02 million, 27.1% more than in 2023.

Financial Statements

Analyst Summary

According to 6 analysts, the average rating for ATYR stock is "Buy." The 12-month stock price target is $8.88, which is an increase of 819.64% from the latest price.

Price Target
$8.88
(819.64% upside)
Analyst Consensus: Buy
Stock Forecasts

News

ATYR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In aTyr To Contact Him Directly To Discuss Their Options If you purchased or acquired se...

1 day ago - PRNewsWire

aTyr Pharma, Inc.'s (ATYR) Failed Drug Trial Spurs Securities Lawsuit -- Hagens Berman

SAN FRANCISCO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- A federal class-action lawsuit has been filed against aTyr Pharma, Inc. (NASDAQ: ATYR) following a devastating 83% drop in the biotech company's stock ...

2 days ago - GlobeNewsWire

aTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - ATYR

LOS ANGELES , Oct. 20, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of aTyr Pharma, Inc. ("aTyr" or "the Company") (NASDAQ: ATYR) for violati...

4 days ago - PRNewsWire

aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT Study Failure Drives Shares 80% Lower -- Hagens Berman

SAN FRANCISCO, Oct. 09, 2025 (GLOBE NEWSWIRE) -- On September 15, 2025, investors in aTyr Pharma, Inc. (NASDAQ: ATYR) saw the price of their shares crater over 80% after the company reported that its ...

15 days ago - GlobeNewsWire

aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT Study Failure Drives Shares 80% Lower – Hagens Berman

SAN FRANCISCO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- On September 15, 2025, investors in aTyr Pharma, Inc. (NASDAQ: ATYR) saw the price of their shares crater over 80% after the company reported that its ...

21 days ago - GlobeNewsWire

Ethos Technologies Targets IPO Amid Positive Insurance Offerings

Ethos Technologies Inc. has filed for a $100 million IPO and provides a three-sided digital life insurance marketplace platform. LIFE is growing rapidly and profitably, with strong revenue, gross marg...

Other symbols: LIFE
24 days ago - Seeking Alpha

aTyr Pharma Presents Additional Findings from Phase 3 EFZO-FIT™ Study in Late-Breaking Oral Abstract at the European Respiratory Society (ERS) Congress 2025

aTyr Pharma Presents Additional Findings from Phase 3 EFZO-FIT™ Study in Late-Breaking Oral Abstract at the European Respiratory Society Congress 2025

24 days ago - GlobeNewsWire

Ethos Files Registration Statement for Proposed Initial Public Offering

AUSTIN, Texas, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Ethos, a leading life insurance technology company on a mission to democratize access to life insurance, today announced that it filed a registration ...

Other symbols: LIFE
4 weeks ago - GlobeNewsWire

aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT™ Study Failure Drives Shares 80% Lower -- Hagens Berman

SAN FRANCISCO , Sept. 23, 2025 /PRNewswire/ -- On September 15, 2025, investors in aTyr Pharma, Inc. (NASDAQ: ATYR) saw the price of their shares crater over 80% after the company reported that its la...

4 weeks ago - PRNewsWire

aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT Study Failure Drives Shares 80% Lower -- Hagens Berman

SAN FRANCISCO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- On September 15, 2025, investors in aTyr Pharma, Inc. (NASDAQ: ATYR) saw the price of their shares crater over 80% after the company reported that its...

4 weeks ago - GlobeNewsWire

Top 3 Health Care Stocks That May Explode In September

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: BSXRVPH
5 weeks ago - Benzinga

Foundation for Sarcoidosis Research Reacts to the Announcement of aTyr Pharma's Phase 3 Clinical Trial Results

CHICAGO, Sept. 17, 2025 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR) expresses both solidarity and resolve as aTyr Pharma announced that its Phase 3 trial of efzofitimod in pulmon...

5 weeks ago - GlobeNewsWire

aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FITÔ Study Failure Drives Shares 80% Lower -- Hagens Berman

SAN FRANCISCO , Sept. 17, 2025 /PRNewswire/ -- On September 15, 2025, investors in aTyr Pharma, Inc. (NASDAQ: ATYR) saw the price of their shares crater over 80% after the company reported that its la...

5 weeks ago - PRNewsWire

ATyr Pharma, Inc. (ATYR) Announces Top Line Results For The Phase III EFZO-FIT Study Of Efzofitimod In Pulmonary Sarcoidosis (Transcript)

aTyr Pharma, Inc. (NASDAQ:ATYR) Announces Top Line Results for the Phase III EFZO-FIT Study of Efzofitimod in Pulmonary Sarcoidosis September 15 2025 11:00 AM EDT Company Participants Ashlee Dunston ...

5 weeks ago - Seeking Alpha

aTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – ATYR

LOS ANGELES--(BUSINESS WIRE)---- $ATYR--aTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – ATYR.

5 weeks ago - Business Wire

ATyr Pharma Stock Sinks, Plans FDA Review After Mixed Phase 3 Results

Biotech firm aTyr Pharma Inc. ATYR plummeted over 81% at last check on Monday, with a session volume of 34.7 million compared to the average volume of 4.83 million as per data from Benzinga Pro.

5 weeks ago - Benzinga

BREAKING: aTyr Pharma Shares Plummet 80%; Investors Should Contact Block & Leviton to Potentially Recover Losses

BOSTON, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Block & Leviton is investigating aTyr Pharma, Inc. (Nasdaq: ATYR) for potential securities law violations.

5 weeks ago - GlobeNewsWire

aTyr Pharma's lung disease drug misses main goal in late-stage trial

aTyr Pharma said on Monday its experimental drug had failed to meet the main goal in a late-stage study testing it in patients with a type of lung disease known as pulmonary sarcoidosis, a disease imp...

5 weeks ago - Reuters

aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis

Study did not meet primary endpoint in change from baseline in mean daily oral corticosteroid (OCS) dose at week 48, although clinical benefit for efzofitimod observed across multiple study parameters...

5 weeks ago - GlobeNewsWire

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-cl...

7 weeks ago - GlobeNewsWire

aTyr Pharma Announces Second Quarter 2025 Results and Provides Corporate Update

SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-cla...

2 months ago - GlobeNewsWire

Insurtech Leader Ethos Adds Industry Veteran William Wheeler to Board of Directors

AUSTIN, Texas, July 30, 2025 (GLOBE NEWSWIRE) -- Ethos, a leading life insurance technology company on a mission to democratize access to life insurance, today announced the appointment of William J. ...

Other symbols: LIFE
3 months ago - GlobeNewsWire

aTyr Pharma Announces Last Patient Visit in Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis

SAN DIEGO, July 22, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-cla...

3 months ago - GlobeNewsWire

aTyr Pharma to be Added to the Russell 2000® and Russell 3000® Indexes

SAN DIEGO, June 26, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-cla...

4 months ago - GlobeNewsWire

aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)

Three out of four efzofitimod-treated diffuse SSc-ILD patients showed clinically important improvement based on the modified Rodnan Skin Score (mRSS) assessment at 12 weeks. Efzofitimod was generally ...

5 months ago - GlobeNewsWire